Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2
Open Access
- 1 November 2005
- journal article
- research article
- Published by American Society for Microbiology in Journal of Virology
- Vol. 79 (21) , 13199-13208
- https://doi.org/10.1128/jvi.79.21.13199-13208.2005
Abstract
Hepatitis C (HCV) E2 glycoprotein is involved in virus attachment and entry, and its structural organization is largely unknown. Characterization of a panel of human monoclonal antibodies (HMAbs) to HCV by competition studies has led to an immunogenic organization model of E2 with three domains designated A, B, and C and epitopes in each domain having similar structural and functional properties. Domain A contains nonneutralizing epitopes, and domains B and C contain neutralizing epitopes. The isolation and characterization of three new HMAbs within domain A for a total of six provide support for this model. All six domain A HMAbs do not neutralize HCV retroviral pseudotype particle (HCVpp) infection on Huh-7 cells, and all six HMAbs have similar binding affinity and maximum binding, Bmax, a relative indicator of epitope density, as other neutralizing HMAbs, suggesting that neutralization is epitope specific and not by binding to any surface epitope. The dose-dependent neutralizing activity of CBH-7, an HMAb to a domain C epitope in spatial proximity to domain A, and of CBH-5, a domain B HMAb to a more distant epitope, were tested in the presence and absence of each domain A HMAb. No enhancement or reduction in CBH-7 or CBH-5 neutralizing activity was observed, indicating that the potential induction of nonneutralizing antibodies should not be a central issue for HCV vaccine design. To assess whether domain A is involved in the structural changes as part of a pH-dependent virus envelope fusion process, changes in antibody binding patterns to normal pH and acid pH-treated HCVpp were measured. Antibody binding affinity of HMAbs to HCVpp was not affected by low pH. However, the Bmax values for low-pH-treated HCVpp with antibodies to domain A increased 46%, for domain C (CBH-7) they increased 23%, and for domain B (CBH-5) there was a decrease of 12%. Collectively, the organization and function of HCV E2 antigenic domains are roughly analogous to the large envelope glycoprotein E organizational structure for other flaviviruses with three distinct structural and functional domains.Keywords
This publication has 26 references indexed in Scilit:
- The Fusion Glycoprotein Shell of Semliki Forest VirusCell, 2001
- Human Monoclonal Antibodies That Inhibit Binding of Hepatitis C Virus E2 Protein to CD81 and Recognize Conserved Conformational EpitopesJournal of Virology, 2000
- A model for the hepatitis C virus envelope glycoprotein E2Proteins-Structure Function and Bioinformatics, 2000
- Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptorProceedings of the National Academy of Sciences, 1999
- Low density lipoprotein receptor as a candidate receptor for hepatitis C virusJournal of Medical Virology, 1999
- Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardizationArchiv für die gesamte Virusforschung, 1998
- CD81 (TAPA-1): A MOLECULE INVOLVED IN SIGNAL TRANSDUCTION AND CELL ADHESION IN THE IMMUNE SYSTEMAnnual Review of Immunology, 1998
- The molecular basis of virulence of the encephalitogenic flaviviruses.Journal of General Virology, 1997
- A quantitative test to estimate neutralizing antibodies to the hepatitis C virus: cytofluorimetric assessment of envelope glycoprotein 2 binding to target cells.Proceedings of the National Academy of Sciences, 1996
- The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolutionNature, 1995